SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-111534
Filing Date
2024-12-23
Accepted
2024-12-23 09:04:11
Documents
3
Period of Report
2024-12-23

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0225725-6k_neuro.htm 6-K 11521
2 PRESS RELEASE, DATED DECEMBER 23, 2024, ENTITLED "NEUROSENSE THERAPEUTICS ENTERS ea022572501ex99-1_neuro.htm EX-99.1 19798
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8837
  Complete submission text file 0001213900-24-111534.txt   44705
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 241570252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)